Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alkermes Submits Vivitrex NDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Alkermes' Vivitrex would be the first alcohol dependence treatment available in a once-monthly injection if FDA approves the NDA submitted March 31

You may also be interested in...



Cephalon/Alkermes Vivitrex User Fee Date Extended

FDA has extended the user fee date for Cephalon's and Alkermes' alcohol dependency therapy Vivitrex (naltrexone) by three months to Dec. 30, the companies announced Sept. 20

Cephalon/Alkermes Vivitrex User Fee Date Extended

FDA has extended the user fee date for Cephalon's and Alkermes' alcohol dependency therapy Vivitrex (naltrexone) by three months to Dec. 30, the companies announced Sept. 20

Vivitrex Will Launch With 25-100 Member Sales Force, Alkermes Says

The Vivitrex sales team will target 6,000 specialists that treat alcohol-dependent patients, CEO Pops says. Alkermes will then look to a marketing partner to expand Vivitrex use beyond the 2.3 mil. initial patient population, he says. Alkermes expects approval in 2006.

Topics

UsernamePublicRestriction

Register

ID020288

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel